VolitionRx Limited (VNRX)

Market Cap	11.50M -77.1%
Revenue (ttm)	2.47M +88.5%
Net Income	-24.60M
EPS	-4.20
Shares Out	8.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	319,985
Open	1.360
Previous Close	1.460
Day's Range	1.360 - 1.480
52-Week Range	1.300 - 18.800
Beta	1.04
Analysts	Buy
Price Target	20.21 (+1,364.49%)
Earnings Date	May 14, 2026

About VNRX

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s c...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cameron Reynolds
• Employees: 67
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: VNRX
• Website: https://volition.com

Financial Performance

In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price target is $20.21, which is an increase of 1,364.49% from the latest price.

Price Target

$20.21

(1,364.49% upside)

Analyst Consensus: Buy